Lexology December 5, 2024
McDermott Will & Emery

The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country. This On the Subject considers the outlook for pharmacy regulation under the second incoming Trump administration and a unified Republican Congress, as well as state-level pharmacy policies that may advance as Republican public policy momentum builds.

In Depth

In its second term, the Trump administration is likely to pursue many of the priorities left unfinished at the end of its first term. With respect to pharmacy regulation, during President-elect Trump’s first term, Congress enacted the Know the Lowest Price Act and the Patients’ Right to Know Drug Prices Act. These two acts prohibited “gag clauses”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Govt Agencies, Pharma, Pharma / Biotech
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices

Share This Article